A role for helix 3 of the TRβ ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone

被引:103
作者
Collingwood, TN
Wagner, R
Matthews, CH
Clifton-Bligh, RJ
Gurnell, M
Rajanayagam, O
Agostini, M
Fletterick, RJ
Beck-Peccoz, P
Reinhardt, W
Binder, G
Ranke, MB
Hermus, A
Hesch, RD
Lazarus, J
Newrick, P
Parfitt, V
Raggatt, P
de Zegher, F
Chatterjee, VKK
机构
[1] Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England
[2] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA
[3] Ist Clin Humanitas, Milan, Italy
[4] Univ Essen Gesamthsch Klinikum, Abt Endokrinol, D-4300 Essen, Germany
[5] Univ Tubingen, Kinderklin, D-7400 Tubingen, Germany
[6] Univ Nijmegen Hosp, Dept Endocrinol, NL-6500 HB Nijmegen, Netherlands
[7] Univ Wales Coll Med, Dept Med, Cardiff CF4 4XN, S Glam, Wales
[8] Kidderminster Gen Hosp, Dept Med, Kidderminster, England
[9] Royal S Hants Hosp, Dept Endocrinol, Southampton SO9 4PE, Hants, England
[10] Addenbrookes Hosp, Dept Clin Biochem, Cambridge, England
[11] Katholieke Univ Leuven, Dept Paediat, B-3001 Leuven, Belgium
基金
英国惠康基金;
关键词
coactivator; dominant negative; resistance to thyroid hormone; transactivation; thyroid receptors;
D O I
10.1093/emboj/17.16.4760
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Resistance to thyroid hormone (RTH) has hitherto been associated with thyroid hormone beta receptor (TR beta) mutations which cluster in two regions (alpha alpha 310-353 and alpha alpha 429-461) of the hormone-binding domain and closely approximate the ligand-binding cavity, Here, we describe a third cluster of RTH mutations extending from alpha alpha 234-282 which constitute a third boundary of the ligand pocket. One mutant, T277A, exhibits impaired transactivation which is disproportionate to its mildly reduced ligand affinity (K-a), T3-dependent recruitment of coactivators (SRC-1, ACTR) by mutant receptor-RXR heterodimers was reduced in comparison with wild-type. Cotransfection of SRC-1 restored transactivation by T277A, In the TRP crystal structure this helix 3 residue is surface-exposed and is in close proximity to residues L454 and E457 in helix 12 which are known to be critical for coactivator interaction, suggesting that they all constitute part of a receptorcoactivator interface. The transcriptional function of other mutants (A234T, R243W/Q, A268D, Delta 276I, A279V, R282S) in this cluster correlated with their reduced K-a and they inhibited wild-type TR beta action in a dominant negative manner. DNA binding, heterodimerization and corepressor recruitment were preserved in all mutants, signifying the importance of these attributes for dominant negative activity and correlating with the absence of natural mutations in regions bordering the third cluster which mediate these functions.
引用
收藏
页码:4760 / 4770
页数:11
相关论文
共 55 条
  • [1] GENETIC-ANALYSIS OF 29 KINDREDS WITH GENERALIZED AND PITUITARY RESISTANCE TO THYROID-HORMONE - IDENTIFICATION OF 13 NOVEL MUTATIONS IN THE THYROID-HORMONE RECEPTOR-BETA GENE
    ADAMS, M
    MATTHEWS, C
    COLLINGWOOD, TN
    TONE, Y
    BECKPECCOZ, P
    CHATTERJEE, KK
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (02) : 506 - 515
  • [2] CHARACTERIZATION OF THE LIGAND-DEPENDENT TRANSACTIVATION DOMAIN OF THYROID-HORMONE RECEPTOR
    BARETTINO, D
    RUIZ, MDMV
    STUNNENBERG, HG
    [J]. EMBO JOURNAL, 1994, 13 (13) : 3039 - 3049
  • [3] A POINT MUTATION (ALA229 TO THR) IN THE HINGE DOMAIN OF THE C-ERBA-BETA THYROID-HORMONE RECEPTOR GENE IN A FAMILY WITH GENERALIZED THYROID-HORMONE RESISTANCE
    BEHR, M
    LOOS, U
    [J]. MOLECULAR ENDOCRINOLOGY, 1992, 6 (07) : 1119 - 1126
  • [4] CRYSTAL-STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE HUMAN NUCLEAR RECEPTOR RXR-ALPHA
    BOURGUET, W
    RUFF, M
    CHAMBON, P
    GRONEMEYER, H
    MORAS, D
    [J]. NATURE, 1995, 375 (6530) : 377 - 382
  • [5] NUCLEAR FACTOR RIP140 MODULATES TRANSCRIPTIONAL ACTIVATION BY THE ESTROGEN-RECEPTOR
    CAVAILLES, V
    DAUVOIS, S
    LHORSET, F
    LOPEZ, G
    HOARE, S
    KUSHNER, PJ
    PARKER, MG
    [J]. EMBO JOURNAL, 1995, 14 (15) : 3741 - 3751
  • [6] Role of CBP/P300 in nuclear receptor signalling
    Chakravarti, D
    LaMorte, VJ
    Nelson, MC
    Nakajima, T
    Schulman, IG
    Juguilon, H
    Montminy, M
    Evans, RM
    [J]. NATURE, 1996, 383 (6595) : 99 - 103
  • [7] NOMENCLATURE OF THYROID-HORMONE RECEPTOR BETA-GENE MUTATIONS IN RESISTANCE TO THYROID-HORMONE - CONSENSUS STATEMENT FROM THE FIRST WORKSHOP ON THYROID-HORMONE RESISTANCE, JULY 10-11, 1993, CAMBRIDGE, UNITED-KINGDOM
    CHATTERJEE, VKK
    BECKPECCOZ, P
    CHIN, WW
    DEGROOT, LJ
    JAMESON, JL
    NAKAMURA, H
    REFETOFF, S
    USALA, SJ
    WEINTRAUB, BD
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 78 (04) : 990 - 993
  • [8] Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300
    Chen, HW
    Lin, RJ
    Schiltz, RL
    Chakravarti, D
    Nash, A
    Nagy, L
    Privalsky, ML
    Nakatani, Y
    Evans, RM
    [J]. CELL, 1997, 90 (03) : 569 - 580
  • [9] A TRANSCRIPTIONAL CO-REPRESSOR THAT INTERACTS WITH NUCLEAR HORMONE RECEPTORS
    CHEN, JD
    EVANS, RM
    [J]. NATURE, 1995, 377 (6548) : 454 - 457
  • [10] A novel TRβ mutation (R383H) in resistance to thyroid hormone syndrome predominantly impairs corepressor release and negative transcriptional regulation
    Clifton-Bligh, RJ
    de Zegher, F
    Wagner, RL
    Collingwood, TN
    Francois, I
    Van Helvoirt, M
    Fletterick, RJ
    Chatterjee, VKK
    [J]. MOLECULAR ENDOCRINOLOGY, 1998, 12 (05) : 609 - 621